The Predictive Value of Serum Procalcitonin for Non-Invasive Positive Pressure Ventilation in the Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Linlin Liu  
Harrison International Peace Hospital

Ying Luan  
Harrison International Peace Hospital

Ling Xiao  
Harrison International Peace Hospital

Ning Wang  
Harrison International Peace Hospital

Jing Wang  
Harrison International Peace Hospital

Chaobo Cui (✉ pbjvwx@yeah.net )  
Harrison International Peace Hospital  https://orcid.org/0000-0003-4045-2901

Primary research

Keywords: Chronic obstructive pulmonary disease, Non-invasive positive pressure, Procalcitonin, AECOPD

DOI: https://doi.org/10.21203/rs.3.rs-113485/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** This study aimed to estimate the value of serum procalcitonin (PCT) for non-invasive positive pressure ventilation (NIPPV) prediction in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

**Methods:** A total of 220 AECOPD patients were divided into NIPPV group (n=121) and control group (routine treatment, n=99) based on the routine standards and physicians’ experience. Logistic regression analysis was performed to identify the independent factors for NIPPV treatment. Additionally, the predictive values of the factors were measured through receiver operation characteristic (ROC) curve.

**Results:** NIPPV group and control group showed significant differences in respiratory rate (RR), PaO2, PaCO2, pH, oxygenation index, erythrocyte sedimentation rate (ESR), neutrophil, CRP (C-reaction protein), and PCT (P<0.05 for all). PCT, CRP, PaCO2, RR, and neutrophil were independently correlated with NIPPV treatment in AECOPD. ROC curve showed that PCT had superior predictive value, with AUC of 0.899, the sensitivity of 86%, and the specificity of 91.9%. The cut-off value of serum PCT for NIPPV prediction was 88.50 ng/l.

**Conclusion:** AECOPD patients who require NIPPV treatment frequently have high levels of PCT, CRP, PaCO2, RR and neutrophil. Serum PCT may be employed as an indicator for NIPPV treatment in AECOPD patients.

Background

Chronic obstructive pulmonary disease (COPD) is a prevalent lung disease which is characterized by long-term airflow obstruction [1]. The morbidity of COPD is high globally, leading to high death and disability rates [2]. In China, the occurrence rate of COPD varied between 1.20% and 8.87% across different cities [3]. COPD is regulated by the interaction of genetic and environmental factors, and exposures to tobacco and pollutants are considered as the pivotal risk environmental factors [4, 5]. With the aggravation of air pollution, the morbidity of COPD shows increasing tendency, which is predicted as the third reason of deaths around the world by 2020 [2]. COPD may gradually impair the immune lung defense system that makes the cases are more susceptible to infection, and bacterial infections represent a leading reason for acute exacerbation of COPD (AECOPD) [6]. AECOPD is a key event for disease progression, intensive care unit (ICU) admission, medical costs and death among COPD patients [7]. Moreover, AECOPD may result in acute respiratory failure, leading to high disability and death rates. Ventilation is accepted as the first-line treatment for the patients with acute respiratory failure. Non-invasive positive pressure ventilation (NIPPV) has been proved to be a safe approach for treatment of respiratory failure among the COPD patients, and it can avoid trauma and infections [8]. However, the application standards for NIPPV in COPD are broad, and the abuse of NIPPV may result in some complications, including pneumothorax, hypotension, aspiration pneumonia and so on. Therefore, it is necessary to explore novel indicators for NIPPV treatment in COPD.
Bacterial infection has been reported to be responsible for about 50% of AECOPD [9]. Procalcitonin (PCT) is a glycoprotein composed by 116 amino acids, and secreted by the medullary C-glands of the thyroid [10]. Under normal physiological condition, serum PCT is nearly undetectable, but its circulating level is obviously increased with the presence of bacterial infections, moreover, its expression levels show mild changes under viral infection [11, 12]. Therefore, serum PCT is considered as a promising biomarker for bacterial infection [13]. It has been reported that serum PCT was closely correlated with bacterial respiratory infection, which could guide antibiotic administration in AECOPD patients [14]. However, the predictive value of serum PCT for NIPPV treatment among AECOPD patients still remains unclear.

In this study, the predictive performance of serum PCT for NIPPV treatment in AECOPD was measured. The receiver operation characteristic (ROC) curve was plotted to obtain the cut-off value of serum PCT, which may further improve the NIPPV management among AECOPD patients.

**Methods**

**Study subjects**

A total of 220 AECOPD cases who admitted the Respiratory general ward of our hospital between January 2017 and December 2017 were prospectively included in our study. All the patients signed the written informed consents. The study was approved by the Ethic committee of the hospital.

The inclusion criteria of the AECOPD cases were as follows: 1) The cases were diagnosed with COPD according to the gold guidelines [15], with a ration of forced expiratory volume in the first second (FEV1) to forced vital capacity less than 70% in post-bronchodilator spirometry, and with the presence of worse respiratory symptoms that beyond normal day-to-day changes, the cases were confirmed as AECOPD. 2) The patients were older than 40 years. In addition, with the presence of the following conditions, the patients would be excluded: 1) pregnancy; 2) other lung disease, such as asthma, bronchiectasis, pneumonia, tuberculosis, etc; 3) other diseases that might influence serum PCT levels, such as septicemia, lung and extrapulmonary malignancies; 4) antibiotic treatment history before admission; 5) combined with other organ failures; 6) critical conditions that needed to be admitted to intensive ICU for endotracheal intubation; 7) poor therapy compliance.

**Grouping**

All the patients met the criteria of admission to the general respiratory ward in the acute exacerbation period of COPD. The patients were divided into NIPPV and control groups according to the routine standards and. The indications for NIPPV treatment were as follows: 1) moderate to severe dyspnea clinical characterized by respiratory distress, with respiratory rate (RR) > 24 times/min; 2) using the accessory respiratory muscles or paradoxical respiration; 3) abnormal blood gas (pH < 7.35, PCO2 > 45 mmHg, or oxygenation index < 200 mmHg). The two groups were matched in age and gender.
The baseline characteristics of the participants were collected from their medical records, regarding demographic characteristics, laboratory testing data, as well as the clinical characteristics, and complications.

**Treatments**

All the patients received routine treatments, including anti-infection treatments, anti-tussive and expectorant treatments, anti-asthmatic treatments and so on. In addition, NIPPV treatment was performed by BiPAP through nose mask. The breathing mode was S/T mode, and the minimum inspiratory pressure was set as 8 mmHg, and the maximum was 20 mmHg. The minimum inspiratory pressure was 4 mmHg, and the maximum value was 12 mmHg. The oxygen flow rate was 5–8 l/min, and the range of inhaled oxygen concentration was 35%-60%. The ventilator was timely adjusted according to the vital signs, and the oxygen saturation was kept above 90%. The detection indicators were measured before and on the first, third and fifth day after treatment.

**Laboratory tests**

The lung function of the patients were measured by Master-Screen pulmonary function meter. Blood routine examinations were performed using antumatic biochemical analyzer. Serum PCT detection was performed by chemiluminescence method, and the normal range of serum PCT was 0-1.5 ng/ml. Serum PCT > 2.5 ng/ml indicated the positive bacterial infection. In brief, 2 ml fasting blood sample was collected from every patient, and centrifuged to isolate serum specimens. Then the detection was performed on the fully-auto chemiluminescence immunoassay (CLIA) analyzer Maglumi 1000 from Snibe Diagnostics following the operational introduction.

C-reaction protein (CRP) was measured by nephelometry assay, and the procedures were carried out following the recommendations of the manufacturer. The normal range of CRP was 0–3 mg/l, and the value more than 8 mg/l indicated the acute infection.

Blood gas analysis was achieved using ABL80FLEX CO-OX Analyzer (Radiometer medical Aps, USA).

**Statistical analysis**

The data analysis was performed using SPSS 18.0 software. The continuous data were expressed as mean ± standard deviation (SD), and their distributions were measured by Kolmogorov-Smirnov Z test. The comparisons of continuous data between two groups were performed by student’s t test (normal distribution) or Mann-Whitney u test (non-normal distribution). The categorical variables were recorded as case number with percentages, and their comparisons were carried out by chi-square test. Logistic regression model was adopted to explore the risk factors for NIPPV treatment among AECOPE patients. The predictive values of serum PCT for NIPPV treatment in AECOPE patients were estimated through receiver operation characteristic (ROC) curve. All the tests were two-tailed, and P values less than 0.05 indicated the statistical significance.

**Results**
Baseline characteristics of the study population

A total of 220 AECOPD cases were included in our study, including 115 males (52.27%) and 105 (47.73%) females, and their average age was 66.14 ± 9.92 years. The mean BMI value of the participants was 24.2 ± 1.94 kg/m². The COPD curse of the patients was 5.93 ± 1.53 years, and their mean AECOPD duration was 3.15 ± 2.01 days. The smoking index was 317.85 ± 167.31, and Glasgow Coma scale (GSC) score was 8.81 ± 3.33. 88 (40%) cases were diagnosed with hypertension, 89 (40.45%) cases were diabetes mellitus, and 90 (40.91%) cases were combined with coronary heart disease (CHD). The mean FEV1/FVC was 48.2 ± 5.16, RR was 32.47 ± 4.91 beats/min, PaO2 was 40.33 ± 6.25 mmHg, PaCO2 was 58.77 ± 12.79, oxygenation index was 186.44 ± 54.75 mmHg, and pH value was 7.25 ± 0.18. Laboratory tests suggested that the mean erythrocyte sedimentation rate (ESR) was 28.79 ± 3.07 mm/h, neutrophil was 77.6 ± 6.45%, white blood cell (WBC) was 10.14 ± 1.30 × 10^9/l, C-reaction protein (CRP) was 15.71 ± 7.45 mg/L, and PCT value was 165.14 ± 102.88 ng/l. The baseline characteristics of the study subjects were summarized in Table 1.
| Characteristics                      | Total     | NIPPV group | Control group | P     |
|--------------------------------------|-----------|-------------|---------------|-------|
| Case number                          | 220       | 121         | 99            |       |
| Gender                               |           |             |               | 0.734 |
| Male                                 | 115(52.27%) | 62(51.24%)  | 53(53.54%)    |       |
| Female                               | 105(47.73%) | 59(48.76%)  | 46(46.46%)    |       |
| Age (year)                           | 66.14 ± 9.92 | 66.81 ± 9.86 | 65.32 ± 9.98 | 0.270 |
| BMI (kg/m²)                          | 24.2 ± 1.94 | 24.11 ± 1.97 | 24.3 ± 1.90  | 0.467 |
| COPD course (year)                   | 5.93 ± 1.53 | 5.89 ± 1.63  | 5.98 ± 1.40  | 0.682 |
| AECOPD duration (day)                | 3.15 ± 2.01 | 3.34 ± 2.22  | 2.92 ± 1.71  | 0.121 |
| Smoking index                        | 317.85 ± 167.31 | 303.33 ± 164.41 | 335.60 ± 169.94 | 0.155 |
| GSC score                            | 8.81 ± 3.33 | 9.19 ± 3.48  | 8.34 ± 3.08  | 0.060 |
| Hypertension                         | 88(40%)    | 43(35.54%)  | 45(45.45%)    | 0.135 |
| Diabetes mellitus                    | 89(40.45%) | 45(37.19%)  | 44(44.44%)    | 0.275 |
| CHD                                  | 90(40.91%) | 53(43.8%)   | 37(37.37%)    | 0.335 |
| FEV1/FVC (%)                         | 48.20 ± 5.16 | 48.64 ± 5.10 | 47.67 ± 5.20 | 0.166 |
| RR (beats/min)                       | 32.47 ± 4.91 | 34.62 ± 3.20 | 29.85 ± 5.35 | < 0.001|
| PaO2 (mmHg)                          | 40.33 ± 6.25 | 42.13 ± 6.22 | 38.13 ± 5.56 | < 0.001|
| PaCO2 (mm Hg)                        | 58.77 ± 12.79 | 64.60 ± 11.23 | 51.66 ± 10.87 | < 0.001|
| pH                                   | 7.25 ± 0.18 | 7.20 ± 0.23  | 7.32 ± 0.06  | < 0.001|
| Oxygenation index (mmHg)             | 186.44 ± 54.75 | 162.16 ± 39.44 | 216.12 ± 56.35 | < 0.001|
| ESR (mm/h)                           | 28.79 ± 3.07 | 29.16 ± 2.85 | 28.33 ± 3.28 | 0.044 |
| Neutrophil (%)                       | 77.6 ± 6.45 | 79.58 ± 5.85 | 75.17 ± 6.34 | < 0.001|
| WBC (× 10⁹/L)                        | 10.14 ± 1.30 | 10.02 ± 1.32 | 10.27 ± 1.27 | 0.160 |
| CRP (mg/L)                           | 15.71 ± 7.45 | 19.47 ± 7.43 | 11.11 ± 4.21 | < 0.001|
| PCT (ng/l)                           | 165.14 ± 102.88 | 233.58 ± 85.75 | 81.48 ± 42.37 | < 0.001|

Notes: COPD: chronic obstructive pulmonary disease; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; CHD: Coronary heart disease; BMI: body mass index; GCS: Glasgow Coma scale; RR: Respiratory rate; CRP: c-reaction protein; PCT: procalcitonin; ESR: erythrocyte sedimentation rate.
The comparison between NIPPV and control groups

According to the therapeutic strategies, the patients were divided into NIPPV group (n = 121) and control group (n = 99). Statistical analyses demonstrated that NIPPV group and control group showed significant differences in RR (34.62 ± 3.20 vs. 29.85 ± 5.35, P < 0.001), PaO2 (42.13 ± 6.22 vs. 38.13 ± 5.56, P < 0.001), PaCO2 (64.60 ± 11.23 vs. 51.66 ± 10.87, P < 0.001), pH (7.20 ± 0.23 vs. 7.32 ± 0.06, P < 0.001), oxygenation index (162.16 ± 39.44 vs. 216.12 ± 56.35, P < 0.001), ESR (29.16 ± 2.85 vs. 28.33 ± 3.28, P = 0.044), neutrophil (79.58 ± 5.85 vs. 75.17 ± 6.34, P < 0.001), CRP (19.47 ± 7.43 vs. 11.11 ± 4.21, P < 0.001), and PCT (233.58 ± 85.78 vs. 81.48 ± 42.37, P < 0.001) (Fig. 1). Meanwhile, the two groups did not show obvious differences in gender (P = 0.734), age (P = 0.270), BMI (P = 0.467), COPD course (P = 0.682), AECOPD duration (P = 0.121), smoking index (P = 0.155), GSC score (P = 0.060), FEV1/FVC (P = 0.166), the occurrences of hypertension, diabetes mellitus, or CHD (P > 0.05 for all) (Table 1).

The related factors for NIPPV treatment among AECOPD patients

Logistic regression model was adopted to identify the independently related factors for NIPPV treatment among AECOPD patients. The results suggested that PCT (OR = 1.035, 95%CI: 1.017–1.053, P < 0.001), CRP (OR = 1.170, 95%CI: 1.013–1.351, P = 0.033), PaCO2 (OR = 1.170, 95%CI: 1.054–1.300, P = 0.003), RR (OR = 1.396, 95%CI: 1.074–1.814, P = 0.013), and neutrophil (OR = 1.154, 95%CI: 1.004–1.327, P = 0.043) were independently correlated with NIPPV treatment in the patients diagnosed with AECOPD (Table 2).

| Variables | OR   | 95%CI          | P       |
|-----------|------|----------------|---------|
| PCT       | 1.035| 1.017–1.053    | < 0.001 |
| CRP       | 1.170| 1.013–1.351    | 0.033   |
| PaCO2     | 1.170| 1.054–1.300    | 0.003   |
| RR        | 1.396| 1.074–1.814    | 0.013   |
| Neutrophil| 1.154| 1.004–1.327    | 0.043   |

The predictive value of the indicators for NIPPV treatment in AECOPD patients

In order to estimate the values of the independent factors for NIPPV prediction in AECOPD cases, ROC analyses were performed. As displayed in Fig. 2, all the independent factors could be used for prediction of NIPPV treatment. The AUC value, sensitivity, specificity and cut-off values of the factors were shown in Table 3. Compared to other factors, PCT showed superior predictive value, with the AUC value of 0.899,
the sensitivity of 86%, and the specificity of 91.9%. The cut-off value of serum PCT for NIPPV prediction was 88.50 ng/l.

| Variables       | AUC  | Sensitivity | Specificity | Cut-off value |
|-----------------|------|-------------|-------------|---------------|
| RR (beats/min)  | 0.759| 100%        | 48.5%       | 29.50         |
| PaCO2 (mm Hg)   | 0.793| 71.9%       | 76.8%       | 57.50         |
| Neutrophil (%)  | 0.687| 93.4%       | 36.4%       | 71.50         |
| CRP (mg/L)      | 0.847| 67.8%       | 88.9%       | 14.50         |
| Serum PCT (ng/l)| 0.899| 86%         | 91.9%       | 88.50         |

**Discussion**

COPD is a frequently diagnosed chronic disease, with high mortality and morbidity. AECOPD refers the acute situation of COPD featured by the worsening of the patient’s respiratory symptoms [16]. Bacterial infection is a leading reason for AECOPD, and antibiotic treatment is necessary for the patients. In addition to antibacterial treatment, the appropriate NIPPV treatment could shorten the hospitalization time, improve the pain, and reduce the need of endotracheal intubation [17]. However, there are no credible indicators for application of NIPPV among AECOPD patients. In this study, we estimated the predictive value of serum PCT for NIPPV treatment in AECOPD patients. The results suggested that serum PCT levels were significantly different between the cases in NIPPV group and control group. Serum PCT was independently correlated with NIPPV treatment, which might be employed as an indicator for NIPPV treatment in AECOPD patients.

For COPD patients, the long-term airflow obstruction could impair their immune lung defense systems, which make the patients more easily to be infected by bacteria, leading to AECOPD [18]. Bacterial infection and inflammation play important roles in progression of AECOPD. Circulating PCT level is considered to be a specific indicator for bacterial infection, and its levels are closely correlated with infection severity [19]. In the current study, 220 AECOPD patients were divided into NIPPV group and control group according to the routine standards and physicians’ experience. The comparison analysis suggested that compared to those in control group, the individuals in NIPPV group were more likely to show high RR, PaO2, PaCO2, ESR, neutrophil, CRP and PCT levels, as well as low pH and oxygenation index. All the results demonstrated the aggressive inflammation, severe infection, and poor pulmonary function of NIPPV cases. Logistic regression analysis suggested that PCT, CRP, PaCO2, RR, and neutrophil were independently correlated with NIPPV treatment in AECOPD. The study carried out by Sarika et al. suggested that PCT level was significantly elevated in AECOPD patients, compared to stable COPD patients [20]. Hamid Borsi et al. reported that serum PCT might be employed as a biomarker for the
differentiation of AECOPD patients from stable COPD patients [21]. All the data revealed the close relationship between serum PCT and COPD progression.

The appropriate application of NIPPV treatment could help improve the clinical prognosis of AECOPD patients, but the abuse of NIPPV may lead to some serious complications, such as pneumothorax, hypotension, aspiration pneumonia, and so on [22, 23]. Therefore, the specific indicators are necessary to guide NIPPV treatment in AECOPD patients. In our study, ROC curve demonstrated that PCT, CRP, PaCO2, RR, and neutrophil could distinguish between NIPPV group and control group. Moreover, compared to other indicators, PCT showed superior values, with better AUC, sensitivity and specificity. Serum PCT might be adopted as an indicator to guide NIPPV treatment among AECOPD patients. Serum PCT had been confirmed as an indicator for antibiotic treatment of AECOPD. A meta-analysis carried out by Li et al. demonstrated that the antibiotic treatment guided by PCT showed similar efficacy and safety with standard antibiotic treatment, and has fewer antibiotic prescriptions [24]. Moreover, the AECOPD patients with high serum PCT levels were more likely to undergo NIPPV failure [25]. The present study might be the first study to explore the predictive value of serum PCT for NIPPV treatment in COPD patients.

Several limitations in current study should be stated. Firstly, the sample size was relatively small that might reduce the statistical power of our analysis. Secondly, due to the selection criteria, the selection bias might be introduced, and the conclusion was limited by the studied subjects. Thirdly, NIPPV treatment was performed based on routine standards and the physicians’ experience that might influence the analysis results. Therefore, the well-designed prospective studies with large sample size are required to improve our analysis.

Conclusions

In conclusion, AECOPD patients who require NIPPV treatment frequently have high levels of PCT, CRP, PaCO2, RR and neutrophil. Serum PCT may be employed as an indicator for NIPPV treatment in AECOPD patients, and the cut-off value was 88.50 ng/l.

List Of Abbreviations

Procalcitonin (PCT)
Non-invasive positive pressure ventilation (NIPPV)
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
Receiver operation characteristic (ROC)
Respiratory rate (RR)
Erythrocyte sedimentation rate (ESR)
Chronic obstructive pulmonary disease (COPD)
Intensive care unit (ICU)
Non-invasive positive pressure ventilation (NIPPV)
Forced expiratory volume in the first second (FEV1)
Chemiluminescence immunoassay (CLIA)
C-reactive protein (CRP)
Standard deviation (SD)
Glasgow Coma scale (GSC)
Coronary heart disease (CHD)

Declarations

Ethics approval and consent to participate

This study was supported by the Ethics Committee of Harrison International Peace Hospital and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.

The subjects had been informed the objective. Certainly, written consents were signed by every subject in this study.

Consent for publication

We obtaining permission from participants to publish their data.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Competing interests

The authors declare that they have no competing interests.

Funding
authors’ contributions

L.L. and C.C. design of the work; Y.L. the acquisition, analysis, L.X. interpretation of data; N.W. the creation of new software used in the work; J.W. have drafted the work or substantively revised it. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, Wouters EF: Chronic obstructive pulmonary disease. Nature reviews Disease primers 2015, 1:15076.
2. Tashkin DP, Wechsler ME: Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease 2018, 13:335-349.
3. Zhu B, Wang Y, Ming J, Chen W, Zhang L: Disease burden of COPD in China: a systematic review. International journal of chronic obstructive pulmonary disease 2018, 13:1353-1364.
4. Agusti A, Hogg JC: Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. The New England journal of medicine 2019, 381(13):1248-1256.
5. Tuder RM: Bringing Light to Chronic Obstructive Pulmonary Disease Pathogenesis and Resilience. Annals of the American Thoracic Society 2018, 15(Suppl 4):S227-S233.
6. Pavord ID, Jones PW, Burgel PR, Rabe KF: Exacerbations of COPD. International journal of chronic obstructive pulmonary disease 2016, 11 Spec Iss:21-30.
7. Liang L, Li C, Shen Y, Rong H, Jing H, Tong Z: Long-Term Trends in Hospitalization and Outcomes in Adult Patients with Exacerbation of Chronic Obstructive Pulmonary Disease in Beijing, China, from 2008 to 2017. International journal of chronic obstructive pulmonary disease 2020, 15:1155-1164.
8. Liu YJ, Zhao J, Tang H: Non-invasive ventilation in acute respiratory failure: a meta-analysis. Clin Med (Lond) 2016, 16(6):514-523.
9. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, Yang IA: Acute exacerbation of COPD. Respirology 2016, 21(7):1152-1165.
10. Aloisio E, Dolci A, Panteghini M: Procalcitonin: Between evidence and critical issues. Clinica chimica acta; international journal of clinical chemistry 2019, 496:7-12.
11. Creamer AW, Kent AE, Albur M: Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe (Sheff) 2019, 15(4):296-304.
12. Sager R, Kutz A, Mueller B, Schuetz P: Procalcitonin-guided diagnosis and antibiotic stewardship revisited. *BMC medicine* 2017, **15**(1):15.

13. Choi JJ, McCarthy MW: Novel applications for serum procalcitonin testing in clinical practice. *Expert review of molecular diagnostics* 2018, **18**(1):27-34.

14. Ni W, Bao J, Yang D, Xi W, Wang K, Xu Y, Zhang R, Gao Z: Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. *Infect Dis (Lond)* 2019, **51**(9):639-650.

15. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM et al: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. *GOLD Executive Summary*. *American journal of respiratory and critical care medicine* 2017, **195**(5):557-582.

16. Hillas G, Perlikos F, Tzanakis N: Acute exacerbation of COPD: is it the "stroke of the lungs"? *International journal of chronic obstructive pulmonary disease* 2016, **11**:1579-1586.

17. Duca A, Rosti V, Brambilla AM, Cosentini R: Non-invasive ventilation in COPD exacerbation: how and why. *Internal and emergency medicine* 2019, **14**(1):139-142.

18. Viniol C, Vogelmeier CF: Exacerbations of COPD. *European respiratory review : an official journal of the European Respiratory Society* 2018, **27**(147).

19. Yunus I, Fasih A, Wang Y: The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. *PloS one* 2018, **13**(11):e0206527.

20. Pandey S, Garg R, Kant S, Verma A, Gaur P: Serum procalcitonin levels in chronic obstructive pulmonary disease patients in North Indian Population. *Annals of African medicine* 2019, **18**(2):103-107.

21. Borsi H, Nia EP, Mal-Amir MD, Raji H: Relationship between serum procalcitonin level and chronic obstructive pulmonary disease. *Journal of family medicine and primary care* 2019, **8**(2):738-740.

22. Addala D, Shrimanker R, Davies MG: Non-invasive ventilation: initiation and initial management. *Br J Hosp Med (Lond)* 2017, **78**(9):C140-C144.

23. Steriade AT, Johari S, Sargarovschi N, Necula D, Tudose CE, Ionita D, Bogdan MA, Bumbacea D: Predictors of outcome of noninvasive ventilation in severe COPD exacerbation. *BMC pulmonary medicine* 2019, **19**(1):131.

24. Li Z, Yuan X, Yu L, Wang B, Gao F, Ma J: Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: An updated meta-analysis. *Medicine* 2019, **98**(32):e16775.

25. Wang J, Shang H, Yang X, Guo S, Cui Z: Procalcitonin, C-reactive protein, PaCO2, and noninvasive mechanical ventilation failure in chronic obstructive pulmonary disease exacerbation. *Medicine* 2019, **98**(17):e15171.

**Figures**
Figure 1

The comparisons of RR, PaCO2, pH, oxygenation index, ESR, neutrophil, CRP, and PCT between NIPPV and control groups.
Figure 1

The comparisons of RR, PaCO2, pH, oxygenation index, ESR, neutrophil, CRP, and PCT between NIPPV and control groups.
Figure 1

The comparisons of RR, PaCO2, pH, oxygenation index, ESR, neutrophil, CRP, and PCT between NIPPV and control groups.
Figure 2

ROC curves were plotted to estimate the predictive values of PCT, RR, PaCO2, CRP and neutrophil for NIPPV treatment among the patients with AECOPD.
Figure 2

ROC curves were plotted to estimate the predictive values of PCT, RR, PaCO2, CRP and neutrophil for NIPPV treatment among the patients with AECOPD.
Figure 2

ROC curves were plotted to estimate the predictive values of PCT, RR, PaCO2, CRP and neutrophil for NIPPV treatment among the patients with AECOPD.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- OriginalData1.sav
- OriginalData1.sav
- OriginalData1.sav
- OriginalData2.pzf
- OriginalData2.pzf
• OriginalData2.pzf